Canton Biologics

About Canton Biologics

Canton Biologics is a contract development and manufacturing organization (CDMO) that provides services for large-molecule biopharmaceuticals. The company was founded in January 2016 in Guangzhou, China, by Dr. Xiao Shen, a group of Chinese returnees, and professionals from international biotech and CDMO companies. Dr. Shen has a Ph.D. from the Swiss Federal Institute of Technology and has extensive experience in animal cell culture and recombinant protein expression.

The company offers end-to-end services, from DNA to clinical supply, catering to both domestic and international biopharmaceutical companies. Its service portfolio includes cell line and process development, formulation, bioanalysis, and manufacturing of biologics such as monoclonal antibodies, bispecific antibodies, and recombinant proteins. The firm operates several facilities, including a 3,600m² R&D center in Guangzhou, a 12,000m² cGMP commercial manufacturing site in Foshan, and an R&D center in Berlin, Germany, through its acquisition of FyoniBio GmbH in 2022. These facilities support pilot and commercial scale manufacturing with production scales up to 2,000L.

Canton Biologics' business model is centered on providing integrated solutions for the entire drug development lifecycle, from early discovery to commercialization. It serves biopharmaceutical enterprises by offering Chemistry, Manufacturing, and Controls (CMC) development, GMP manufacturing, and global clinical supply. The company has received multiple rounds of funding, including a Series C round in September 2023 that raised over 300 million yuan, led by SDIC Venture Capital. These funds are intended to advance R&D, scale commercial production, and expand its global footprint.